Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2015-02-26 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Summary of Half Year results 2 pages 60.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Imugene announces half-year results for period ended 31 December 2014' and contains detailed financial results for the six months ending 31 December 2014, including loss figures, cash position, operational highlights, and clinical trial updates. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, which aligns with the definition of an Interim / Quarterly Report (IR). The document length is 4375 characters, which is sufficient to contain actual financial data rather than just an announcement or summary. Therefore, this document is best classified as an Interim / Quarterly Report (IR). H1 2015
2015-02-26 English
Appendix 4D - Half Yearly Report and Accounts 25 pages 832.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report for the Half Year Ended 31 December 2014' and contains detailed financial statements such as the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Financial Position, Directors' Report, Auditor's Independence Declaration, and notes to the financial statements. It covers a half-year period, specifically the six months ended 31 December 2014, and includes substantive financial data and analysis. The presence of an independent auditor's review report further supports that this is a formal interim financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2015
2015-02-26 English
Grant of Options to Dr Nick Ede & Appendix 3B 13 pages 402.7KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed announcement regarding the grant of options to an executive (Dr Nick Ede) and includes an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcing new issues of securities, application for quotation of additional securities, and related agreements. The content includes specifics about the number of options, exercise price, expiry date, and compliance with ASX rules. It also contains detailed information about the securities issued, shareholder approvals, and quotation agreements. This type of document is not a financial report, earnings release, or management discussion but rather a formal announcement related to capital changes and securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a simple notice but a full disclosure of a capital change event.
2015-02-26 English
Response to Price Query 3 pages 222.2KB
Regulatory Filings Classification · 100% confidence The document is a letter from Imugene Limited responding to an ASX price query regarding unusual trading activity in the company's securities. It includes the ASX's original query letter and Imugene's detailed response. The content focuses on compliance with ASX Listing Rules, specifically Listing Rule 3.1 about disclosure obligations, and explains the company's awareness of any material information affecting the stock price. There are no financial statements, earnings data, or report attachments. The document is a regulatory communication related to market compliance and disclosure rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-02-19 English
Imugene Receives $230K Research and Development Tax Refund 1
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 18 February 2015 from Imugene Limited about receiving a $230K research and development tax refund. It mentions the refund complements a previously announced capital raising and supports ongoing clinical trials. The text is brief, under 5,000 characters, and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an update on financing and funding related to R&D activities, not a full financial report or earnings release. Therefore, it fits best as a Capital/Financing Update (CAP) since it discusses funding received and its impact on company operations.
2015-02-17 English
Investor Presentation 16 pages 3.1MB
Investor Presentation Classification · 100% confidence The document is a detailed presentation from Imugene Limited dated February 2015, focusing on the company's immuno-oncology therapies, clinical trial status, leadership, investment summary, valuation comparisons, licensing deals, and financial information. It includes forward-looking statements, clinical trial phases, and investment highlights. The document is titled as a 'Proactive Investor Presentation' and contains no formal financial statements or regulatory disclosures typical of annual or interim reports. It is not an earnings release, audit report, or legal proceeding update. The content is consistent with a detailed investor presentation aimed at providing financial, strategic, and clinical development information to investors. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and content confirm it is the presentation itself, not just an announcement or summary.
2015-02-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.